SHH · 688185.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:00 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
CanSino Biologics Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
CanSino Biologics Inc.’s next earnings report is currently expected on Mar 30, 2027, with estimated earnings per share of CN¥0.32. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CanSino Biologics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CS-2023 to treat meningitis; CS-2028 for treating multivalent conjugate vaccine; CS-2032 for hingles; CS-2036 to treat polio; CS-2047 for treating tetanus; and CS-2201 DTcP for combination vaccine. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 20, 2025 |
| -CN¥0.01+92.28% vs estimate |
| CN¥237.00M-5.59% vs estimate |
| Q1 2025 | Apr 29, 2025 | -CN¥0.05-3,167.83% vs estimate | CN¥134.90M |
|---|
| Q4 2024 | Mar 25, 2025 | -CN¥0.63-2.78% vs estimate | CN¥279.26M+0.14% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥13.49+CN¥0.61 (+4.74%)
Chongqing Zhifei Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
CN¥23.05-CN¥0.12 (-0.52%)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 60.71% below the high.
CN¥12.31-CN¥0.06 (-0.49%)
Beijing Tiantan Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 34.14% below the high.
CN¥10.89-CN¥0.62 (-5.39%)
Walvax Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 35.83% below the high.
CN¥12.07-CN¥0.14 (-1.15%)
Shenzhen Kangtai Biological Products Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.04% below the high.
CN¥26.28+CN¥0.87 (+3.42%)
Chengdu Olymvax Biopharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
CN¥13.95-CN¥0.17 (-1.2%)
Hualan Biological Bacterin Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.96% below the high.
CN¥15.43-CN¥0.36 (-2.28%)
Changchun BCHT Biotechnology Co.’s quoted price sits in the lower half of its reported 52-week range, 36.94% below the high.
